4D Molecular Therapeutics (FDMT) Cash & Equivalents (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Cash & Equivalents data on file, last reported at $72.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $72.5 million, down 45.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $72.5 million (down 45.71% YoY), and the FY2025 annual result was $60.2 million, down 59.66% from the prior year.
• Cash & Equivalents advanced to $72.5 million in Q1 2026 per FDMT's latest filing, from $60.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $275.7 million in Q3 2023 and troughed at $48.6 million in Q3 2025.
• A 5-year average of $140.2 million and a median of $113.5 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents surged 375.84% in 2023, then slumped 74.11% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $52.4 million in 2022, then soared by 375.84% to $249.1 million in 2023, then sank by 40.05% to $149.3 million in 2024, then plunged by 59.66% to $60.2 million in 2025, then grew by 20.33% to $72.5 million in 2026.
• Business Quant data shows FDMT's Cash & Equivalents at $72.5 million in Q1 2026, $60.2 million in Q4 2025, and $48.6 million in Q3 2025.